8-K: Bausch Health Reports Q1 2025 Results: Revenue Up, Focus on Shareholder Value

Bausch Health announced a 5% increase in first quarter 2025 consolidated revenues, alongside ongoing efforts to enhance shareholder value and optimize its capital structure.

Summary

• Bausch Health Companies Inc. reported its first quarter 2025 financial results, with consolidated revenues reaching $2.26 billion, a 5% increase compared to the first quarter of 2024.
• On an organic basis, revenue increased by 6%.
• The company's GAAP net loss attributable to Bausch Health was $58 million.
• Consolidated Adjusted EBITDA attributable to Bausch Health was $661 million, consistent with the prior year period.
• Bausch Health excluding Bausch + Lomb saw its eighth consecutive quarter of year-over-year revenue and Adjusted EBITDA growth, with increases of 6% and 14%, respectively.
• The company successfully completed a $7.9 billion refinancing in early April to extend nearand medium-term maturities.
• Full-year 2025 revenue and Adjusted EBITDA guidance are maintained, while Adjusted Cash Flow from Operations guidance was updated to reflect higher interest expense.
• The company is evaluating all options to unlock shareholder value, including maximizing asset value and share buybacks.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth and successful refinancing, but tempered by the net loss and ongoing economic uncertainties.

Positives

• Consolidated revenues increased by 5% to $2.26 billion in Q1 2025.
• Organic revenue growth was 6%.
• Bausch Health excluding Bausch + Lomb achieved 6% revenue growth and 14% Adjusted EBITDA growth.
• A $7.9 billion refinancing was successfully completed in early April.
• The company received a favorable ruling from the D.C. District Court in Norwich's case against the FDA.
• Salix segment reported revenues were $542 million for the first quarter of 2025, compared with $499 million for the first quarter of 2024, an increase of $43 million, or 9%.

Negatives

• GAAP net loss attributable to Bausch Health was $58 million.
• Consolidated Adjusted EBITDA attributable to Bausch Health was $661 million, consistent with the prior year period.
• International segment reported revenues were $262 million for the first quarter of 2025, compared with $265 million for the first quarter of 2024, a decrease of $3 million, or 1%.

Risks

• The company acknowledges the impact of current market and economic conditions, including inflation, on its business and operations.
• Uncertainty remains regarding the commercial success of new and existing products.
• Challenges to patents and the company's ability to enforce them pose a risk.
• The company's substantial debt and debt service obligations are a continuing risk factor.
• Potential imposition of and adverse changes to duties, tariffs, and other trade protection measures could negatively impact the company.

Future Outlook

The company maintains its full-year 2025 revenue guidance of $9.95 billion to $10.2 billion and Adjusted EBITDA guidance of $3.475 billion to $3.625 billion, while updating its Adjusted Cash Flow from Operations guidance to reflect higher interest expense.

Management Comments

• Thomas J. Appio, Chief Executive Officer, stated, 'We started the year strong, delivering our eighth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, highlighting the broad momentum across our diverse businesses and geographies.'
• Thomas J. Appio, Chief Executive Officer, stated, 'We are laser focused on growing profitably and executing against our strategic priorities, including evaluating all options to unlock shareholder value.'

Industry Context

The announcement reflects Bausch Health's efforts to streamline operations, manage debt, and focus on core growth areas within the pharmaceutical and eye health sectors. The company's performance is being viewed in light of broader industry trends, including the impact of tariffs and global economic conditions.

Comparison to Industry Standards

• Comparing Bausch Health's performance to companies like Johnson & Johnson, Novartis, and AbbVie, which also operate in diversified healthcare segments, reveals that Bausch Health's revenue growth is competitive.
• The successful refinancing of $7.9 billion in debt is a significant step towards improving its financial stability, similar to actions taken by Teva Pharmaceutical Industries to manage its debt load.
• Solta Medical's 33% organic revenue growth is particularly strong compared to the aesthetic device market, where companies like Allergan and Galderma also compete.

Stakeholder Impact

• Shareholders may see increased value through strategic initiatives and potential share buybacks.
• Employees can expect continued focus on growth and operational efficiency.
• Customers will benefit from ongoing product development and market expansion.
• Creditors will see improved financial stability through debt refinancing.

Next Steps

• The company will continue to evaluate options to unlock shareholder value, including maximizing the value of assets and share buybacks.
• The company will continue to focus on strengthening its balance sheet.
• The company is awaiting Canadian and European response to regulatory submissions for Clear + Brilliant Touch.
• The company is on track for top-line Phase 3 results for RED-C anticipated by early 2026.

Key Dates

Keywords

Bausch Health, Financial Results, Q1 2025, Revenue, Adjusted EBITDA, Refinancing, Shareholder Value, Pharmaceuticals, Bausch + Lomb